Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OB-002 monotherapy in refractory metastatic cancers
NCT05940844Phase 1Withdrawn
- Sponsor
- Orion Biotechnology
- Start
- Jan 2024
- Primary completion
- Apr 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 1, open-label trial of OB-002 in metastatic colorectal cancer (mCRC), gastric cancer (GC), breast cancer and 1 more (5 arms), sponsored by Orion Biotechnology. Primary endpoints: Adverse Events at 12 months and Maximum Tolerated Dose at 28 days. Planned start Jan 2024; status: withdrawn.
02
Drugs
OB-002
03
Conditions
metastatic colorectal cancer (mCRC)gastric cancer (GC)breast cancerurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05940844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940844.